Denali Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Hey, good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 40th JPMorgan Healthcare Conference with Denali today. I'm joined by the company's CEO, Ryan Watts, who's going to give a presentation, and then there's going to be some time for Q&A afterwards. So if you do have questions during the presentation, you can use the blue, ask-a-question-button, send them to me, and I can ask them to management once the presentation is done.
So with that, let me pass it over to Ryan.
Jess, thank you. Thank you for the introduction. Very excited to be here today. It's always exciting for us. We get to summarize what's happened over the last year, share data from the last year to set context, but also to present new data and then focus on what's going to happen in 2022, which is an exciting time for us here at Denali.
So I'll start by just
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |